Analyst Ratings For NASDAQ:FLKS – Flex Pharma (NASDAQ:FLKS)
Today, HC Wainwright reiterated its Buy rating on NASDAQ:FLKS – Flex Pharma (NASDAQ:FLKS) with a price target of $40.00.
Some recent analyst ratings include
- 5/3/2018-HC Wainwright Reiterated Rating of Buy.
- 1/25/2018-Ladenburg Thalmann initiated coverage with a Buy rating.
- 1/3/2018-Roth Capital Reiterated Rating of Buy .
- 11/3/2016-JMP Securities Reiterated Rating of Buy.
Recent Insider Trading Activity For NASDAQ:FLKS – Flex Pharma (NASDAQ:FLKS)
NASDAQ:FLKS – Flex Pharma (NASDAQ:FLKS) has insider ownership of 7.62% and institutional ownership of 28.94%.
- On 11/8/2016 Christoph H Westphal, Insider, bought 7,000 with an average share price of $7.31 per share and the total transaction amounting to $51,170.00.
- On 11/7/2016 Christoph H Westphal, Insider, bought 8,870 with an average share price of $5.70 per share and the total transaction amounting to $50,559.00.
- On 11/7/2016 John P Mccabe, VP, bought 1,650 with an average share price of $6.01 per share and the total transaction amounting to $9,916.50.
- On 6/23/2016 Christoph H Westphal, CEO, bought 2,700 with an average share price of $11.28 per share and the total transaction amounting to $30,456.00.
- On 6/22/2016 Christoph H Westphal, CEO, bought 5,700 with an average share price of $11.05 per share and the total transaction amounting to $62,985.00.
- On 6/21/2016 Christoph H Westphal, CEO, bought 2,800 with an average share price of $11.07 per share and the total transaction amounting to $30,996.00.
- On 6/20/2016 Christoph H Westphal, CEO, bought 6,000 with an average share price of $11.18 per share and the total transaction amounting to $67,080.00.
Recent Trading Activity for NASDAQ:FLKS – Flex Pharma (NASDAQ:FLKS)
Shares of NASDAQ:FLKS – Flex Pharma closed the previous trading session at 4.50 up +0.08 1.81% with 1043 shares trading hands.